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 LONGITUDINAL ANALYSIS OF RENAL FUNCTION USING ZIP GEE ON OLT
TRANSPLANT PATIENTS UNDERGOING NAC PROPHYLAXIS 
Shekhar Mehta, M.S. 
University of Pittsburgh, 2006gan dysfunction is associated with oxidative stress following Orthotropic Liver Transplant 
LT) surgery.  N-Acetyl Cysteine (NAC) is an acetylated form of the amino acid cysteine. 
C is known to replenish glutathione in the bloodstream which helps relieve cell damage 
sed by oxidative stress.  NAC was used in a placebo controlled study to discover its effects on 
an dysfunction caused by oxidative stress following OLT surgery.  A standard NAC 
atment, as used to treat acetaminophen toxicity, was used as a treatment during surgery.  
asures of hepatic and renal dysfunction were recorded at unequally spaced time-points for a 
low-up time of one year.  The Generalized Estimating Equation (GEE) approach was used to 
del continuous hepatic responses.   Discrete renal dysfunction responses are shown to follow 
unique distribution.  This unique distribution was accommodated by the GEE procedure 
posed by Liang and Zeger to produce consistent and efficient estimates of the treatment effect 
NAC.  The estimates produced contradictory results for a hypothesized protective effect of 
C against hepatic dysfunction.  The public health relevance of this work is that NAC 
atment, if shown to be efficacious with respect to renal function, can benefit over six thousand 
T patients each year.  
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1.0  INTRODUCTION 
   
Toxic radicals are known to have a detrimental effect on internal organ tissue[5].  This cell 
damage is especially relevant for organ transplant patients as their immune systems are 
weakened to help prevent organ rejection.  Oxidative stress has been shown to be related to renal 
dysfunction in early post-operative stages of Orthotropic Liver Transplant (OLT)[5]. N-Acetyl 
Cysteine (NAC) is the acetylated form of the amino acid cysteine.  It is rich in thiol groups.  
Thiol groups of glutathione act as competitive inhibitors of toxic radicals for protein substrates. 
NAC helps replenish the thiol groups of glutathione [2].  NAC also effects the concentration of 
nitric oxide in the blood.  Nitric oxide is a powerful vasodilator. Vasodilatation is important 
following liver transplant because it increases dieresis, which helps clear the blood of toxic 
chemicals. Decreases in urinary output are associated with renal dysfunction [14]. Renal 
dysfunction is associated with post-operative mortality rates of OLT patients. The one month 
mortality rate for patients who develop renal dysfunction is fifty percent, while the mortality rate 
for those with normal renal function is close to thirty percent [4]. 
In analysis of the treatment NAC on renal and hepatic functioning status the patient 
population consists of adults who have undergone OLT transplant surgery at the University of 
Pittsburgh Medical Center.  A total of 82 patients were recruited.  Of the 82 patients 8 were 
dropped from the analysis due to cancellation of the procedure, death within the first three days 
following surgery, or unknown treatment status. There are several patient characteristics that 
may influence organ dysfunction. These patient characteristics include an indicator for treatment 
status, age in years, gender (designated by an indicator variable for male gender), amount of red 
blood cells transfused during surgery, and body mass index.  The organ donor characteristics of 
age, in years, and serum sodium level of the donor liver were also recorded.  Tatsuka et. al. have 
proven a strong correlation between donor serum sodium levels and liver graft performance. [13] 
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This donor effect is intuitively expected.  The status of the donor liver will greatly affect the 
condition of the transplant patient.  Patients are randomized at a 1 to 1 ratio to either the 
treatment or placebo group.  In the analyzed patient population there are 39 assigned to placebo, 
and 35 assigned to the NAC treatment. The NAC was prepared by the UPMC Presbyterian 
Pharmacy. The initial treatment consisted of a load dose of 140mg/kg NAC, given by IV, over 
one hour prior to surgery. Then 70mg/kg was administered over one hour every 4 hours for 12 
additional doses. This dosage regime is the standard used for acetaminophen induced toxicity at 
UPMC medical center. The patients in the placebo groups received an identical administration of 
normal saline solution.  All patients were followed for one year with the goal of ascertaining the 
effect of NAC on organ dysfunction.  
The hepatic response data consists of repeated measurements of Alanine Aminotranferase 
(ALT), Aspartate Aminotransferase (AST), Bilirubin, and International Normalized Ratio (INR).  
The time intervals for hepatic responses are unequal.  A baseline measurement was recorded 
before the surgery (day 0).  Measurements were then taken at the following time-points: each 
post-operative day for the first week (day1 - day7), at 1month (day 30), 3month (day 90), 
6month (day 180), and 1year (day 360) for a total of twelve time-points.  ALT is an enzyme that 
is released into the bloodstream by the liver after hepatocytes are damaged or destroyed.  ALT 
catalyzes the transfer of an amino group from alanine to alpha-ketoglutarate, and acts as a 
nitrogen buffer.   This transfer of amino groups is important to renal functioning as well since 
kidney damage causes the retention of toxic, nitrogen rich urea.  AST is also a liver enzyme 
released when hepatocytes are damaged.  AST is found in cardiac and other organ tissues.  Males 
often have higher levels of AST as it is found in a range of muscle tissue types. Bilirubin is a 
product of the destruction of red blood cells.  It is removed from the bloodstream by the liver.  
Bilirubin measures in the blood are indicative of liver functioning status.  INR is a standardized 
measure of prothrombin time.  Prothrombin time measures blood coagulation time.  The 
standardization of INR accounts for differences in the clinical lab conducting the tests. Each lab 
uses a variably prepared tissue factor called thromboplastin, which is a protein used to initiate 
blood coagulation in the test. 
INR = PT testPT normal
ffffffffffffff gISI  
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International Sensitivity Index (ISI) is determined by the manufacturer of the tissue factor. The 
INR of the patient population ranges from 0.6 to 3.7 with normal values between 0.8 and 1.2.  .  
These four measurements together give a sufficient indication of liver functioning status.   
The renal response consists of repeated measure of post-operative Acute Renal Failure 
Scores (ARF) as designated by the RIFLE criteria [7]. The ARF scores are based on levels of 
urinary output and serum creatinine. There are five levels of ARF score: 0 no risk; 1 risk ;  2 
Injury ;  3 Failure ;  4 Persistent ARF ; and 5 End Stage Renal Disease (ESRD). The ARF scores 
were also recorded at unequal time intervals. A baseline measurement was taken before the OLT 
surgery at day0.  ARF responses were then recorded at the following times: post-op at the end of 
treatment day 1, day 7, day 14 , day 21, 1month (day 30), 3month (day 90), 6month (day 180), 
and 1 year (day 360).  The objective of this thesis is to analyze the effect of NAC on hepatic and 
renal functioning status of OLT transplant patients using the GEE approach. Preliminary 
graphical analysis of the responses will be conducted to try to understand the trend of responses 
over the study time.  The patient characteristics between treatment groups will be compared to 
ascertain randomness.  The procedure of GEE will be implemented to estimate the main 
treatment effect on both the hepatic and renal responses.  The effect of the treatment if any will 
give evidence toward a protective effect of NAC on OLT transplant patients  
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1.1 THE GENERALIZED ESTIMATING EQUATION APPROACH 
 
 
The most widely known method to model repeated responses that are assumed to depend on a 
mixture of both discrete and continuous covariates is an extension of the group of Generalized 
Linear Models proposed by Nelder and Wedderburn[12].  This extension was originally 
proposed by the seminal paper Longitudinal Analysis using Generalized Linear Models by Liang 
and Zeger [10]. Liang and Zeger adapted the Generalized Linear Model framework to 
incorporate longitudinal response data.  These extensions use a working correlation structure that 
deals with the correlated longitudinal responses to consistently model the parameter values. Main 
effects estimators are assumed to be consistent without regard to the assumed correlation 
structure [1, p.471]. For example, suppose there is a collection of random variables Yij 
representing the value of a response for the ith patient at replication j = 1 to p. Consider the 
normally distributed case where  Y . Where  i ~ N µ i ,Σi
b c µ i   = E(Yij), a 1 x p vector of repeated 
responses and Var(Yij) = Σ   a p x p matrix with the marginal variances on the main diagonal and 
covariances among the replications elsewhere. Assuming the response depends upon a vector of 
length m of covariate patient characteristics. The model is written as follows: 
g E Y ij
B Cd e =X
k = 1
m β ik X ik  
for a suitable link function g(-). For the normal case the link function is the identity link.  The 
response is directly related to the linear function of covariates.  Estimates of the coefficients of 
the covariates are given by solving the following score equation [1]: 
S β^b c =X
i = 1
N
Di . V i
@ 1 yi@µ
b c = 0 
V i = Ai
1
2
ff
Ri α^
b c
A
i
1
2
ff
 
And the variance of the estimate is given by: 
V β^b c = M 0@ 1 M 1 M 0@ 1
where M 0 =X
i = 1
N
Di . V i
@ 1 Di and M 1 =X
i = 1
N
Di . V i
@ 1 cov Y i
b c
V i
@ 1 Di .
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The solution to the score is evaluated iteratively using the Fisher algorithm: [15] 
β t + 1^ = β t^ + X
i = 1
N
Di . V i
@ 1 Di
HJ IK@ 1B X
i = 1
N
Di . V i
@ 1 yi@µ
b cHJ IK 
Di is a p x m matrix of the derivative of the mean at each time with respect to each parameter. Ai 
is a diagonal matrix of marginal variances of Yi.  As a working covariance matrix Vi should be 
close to the true  Σ   for efficiency of the estimation procedure (the score of beta is consistent 
irrespective of Vi )[2].   Ri is a parameterized correlation matrix with 1 on the main diagonal and 
the parameter vector  α , representing the correlation among repeated measures, everywhere else.  
The most commonly used form of correlation structure is called “exchangeable”, where the 
correlation among any pair of observations is assumed to be constant.  The value of alpha is 
treated as a nuisance in estimating the coefficients.  Several common correlation structures can 
be defined.  “Unstructured” correlation occurs when any pair of repeated observations is 
assumed to have a unique value.  “Auto-regressive” correlation exists when the longitudinal 
measurements show a steadily increasing or decreasing trend.  The correlation between 
successive observations is modeled on the previous response.  Notice that if Ri is the identity 
matrix then the score equation reduces to the quasi-score of a marginal GLM model which 
assumes independence of the repeated measures[11]. 
S β^b c =X
i = 1
N
Di . Ai
1
2
fff
I ni Ai
1
2
fffd e@ 1
yi@µ
b c = 0 
For the linear model, a test of  β k = 0 is a test of the effect of the covariate on the outcome of the 
response.  The Z-statistic is used to test the significance of the coefficients.   
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Z = β k
^
se Bk
^
d effffffffffff~ N 0,1b c [1 , p.578] 
GEE, as applied to normally distributed random variables, will be applied to the continuous 
hepatic responses.  A test of the effect of the NAC treatment on the hepatic response is a test of 
the significance of the coefficient associated with the NAC indicator variable.  The effect of 
NAC on each individual hepatic response will give evidence of the effect of NAC on the liver as 
a whole.  The hepatic responses are associated with cell damage.  If the effect of NAC decreases 
the response then NAC will be shown to be protective against cell damage induced by oxidative 
stress.  
 Suppose the longitudinal response is discrete rather than continuous. In the discrete case 
the parameter estimates of the covariate effects are conveniently handled in a similar manner.  
The only change comes from defining an alternate link function to cope with the discrete 
response. Suppose there is a response defining inclusion into a group of interest, the response 
being “yes” or “no”.  When dealing with binary or categorical response a logit link is frequently 
used. Let Yij ~Bernoulli(p)  then: 
E Y ij
B C = p
logit p^
b c = ln p^
1@ p^
fffffffffhj ik=X
k = 1
m βk X k
 
The logit function is the log of the odds of being in the specified group of interest:  It is assumed 
to be a linear function of the covariates.  The expected risk associated with the outcome of 
interest based on this model is: 
p^ = e
X
k = 1
m βk X ik
1 + eXk = 1
m βk X ik
fffffffffffffffffff 
The estimate of coefficients through the solution to the score equation remains the same.   
 Likewise, suppose the discrete response is a count and assumed to have a poisson 
distribution with parameter lambda.  In this count response case the log link is frequently used to 
model the covariate effects: 
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Y ij ~ Poisson λ` a
E Y ij
B C = λ
ln λ^b c =X
k = 1
m β k X ik
 
The expected count depends on the covariate vector by the inverse transformation given below: 
λ^ = eXk = 1
m βk X k  
As mentioned previously the parameter estimates are obtained using the Fisher algorithm to 
solve the score equation. 
 Now, suppose the longitudinal response is distributed as a mixture of a poisson 
distribution and a bernoulli distribution.  In this situation the response has some probability of 
coming from the bernoulli distribution and the conjugate probability of coming from the poisson 
distribution.  Zero-Inflated Poisson (ZIP) distributions are used for this split distributed type of 
response.  ZIP models are common in situations where the investigator is interested in deviations 
from a perfect state of zero response [6]. There are currently few methods to model longitudinal 
discrete responses that display a ZIP distribution described by Lambert [1].  A random variable 
Y is said to follow a ZIP distribution if Y has the following probability mass function: 
P Y = yb c =
p + 1@ pb ce@ λ , y = 0
1@ p
b c e@ λλ y
y!
ffffffffff, y = 1, 2, 3,…, 0 ≤ p ≤ 1
X^^^
\^
^^Z  
The density above consists of two parts.  Lam et. al.  describes the first part, where y = 0, as the 
structural portion of the density. This is where the outcome is in a “perfect” state of zero 
response.  (1-p) is the mixing probability or “weight” of the second portion called the “sampling” 
portion of the density[8].  Modeling mixed distributions pose problems because there are 
parameters of two different distributions associated with one random variable.  If Y is distributed 
ZIP then: 
Y = 0 , ~Bernoulli p
` a
y , ~ Poisson λ` a with mixing probability 1@ pb c , y ≥ 1
X^\^
Z  
Theoretically the GEE estimation procedure is applicable for models of mixed distribution, 
specifically models of ZIP responses. The GEE approach will be used to model the ARF scores.  
Intuitively the renal response of ARF is expected to be a mixture of a binary response as well as 
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a count response.  Patients who are robust will not exhibit any risk of renal failure over the entire 
one year study time.  They will be apart of the “structural” zero state of the response.  Robust 
patients will remain outside of the group that displays poisson counts.  Patients who develop risk 
following the OLT surgery are expected to fluctuate among the ARF levels of risk which include 
responses of zero risk at some times but could also end in ESRD.  These frail patients will be 
apart of the sampling portion of the ZIP distribution.  The treatment effect of NAC on renal 
dysfunction will be elucidated by assuming the ARF scores are distributed ZIP and modeling the 
mean ARF score as a function of patient characteristics.   
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2.0    APPLICATION OF GEE TO HEPATIC RESPONSE 
The continuous repeated measurements of ALT, AST, Bilirubin, and INR are supposed to be 
correlated for each individual patient over time.  However, the main interest lies in modeling the 
mean of each individual hepatic response and the manner in which the covariate patient 
characteristics, including treatment group, affect the mean response.  Modeling the effect of 
NAC on the four hepatic responses will give an indication of the protective effect of NAC 
following OLT surgery.  The only condition of the GEE approach is to specify the correct 
univariate marginal distribution of the response. Specifying the marginal distribution is 
accomplished by identifying the correct distribution of each response at each time-point. A 
“working assumption” of the correlation structure of the response is ideal since the correlation 
over time is treated as a nuisance.  For hepatic responses the assumed correlation among any two 
measurements is constant.  This assumption of constant correlation is used for two reasons. First, 
since the time intervals are not identical it would be difficult to assume that the correlation 
follows a regular increasing or decreasing pattern over the measured time-points.  Second, the 
purpose of GEE is to treat this correlation as a nuisance to obtain estimates of the parameters.  
Using a single parameter correlation structure leads to efficiency and simplicity of the parameter 
estimations.   
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2.1 PRELIMINARY HEPATIC RESPONSE INVESTIGATION 
As table 1 indicates, the patient characteristics do not differ by treatment group.  If this was the 
case then the patient characteristic may potentially confound the actual results.  For example, if a 
higher proportion of older patients were found in the treatment group then biased main effects 
would result from the model.  The older patients may have worse responses due to their age 
which would hide the treatment effect of NAC. The Wilcoxon rank-sum test was used to 
compare the covariates for the two treatment groups.  The Wilcoxon test is an ideal test of group 
differences for data of unknown distributions. Note that the p-values associated with each of the 
tests are non-significant at up to  α   = 0.12.  The treatment groups are found to be similar with 
respect to the patient characteristics.  Males constituted 70% of the total patient population while 
females made up 30% of the total.  Of the treatment group 70% were male.  Similarly of the 
placebo group 69% were male.  The same proportion of each gender existed in each treatment 
group. 
 
 
 
Table 1: Covariate Group Comparison 
Patient  
Characteristic 
NAC  Placebo 
 P50  P25 P75  P50 P25 P75 *p-value 
Age 61 52 67  60 53 69 0.8453 
RBC 8 5 11  6 4 9 0.1366 
Don. Age 58 40 77  51 40 70 0.4646 
Don. Sodium 146 141 155  146 142 153 0.8347 
BMI 29.21 25.98 33.62  27.21 24.29 32.29 0.1255 
* p-value is a result of the Wilcoxon Ranksum test 
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Figure 1: Lowess smooth over days of ALT and AST 
ALT is the left panel AST is the right panel NAC group in red (lighter) 
 
 
 
A locally weighted smooth-plot (lowess) was applied to all four hepatic responses. The lowess 
method uses a first degree polynomial least squares linear fitting method to smooth the response 
data over time.  The bandwidth of the plots is 0.8.  The bandwidth dictates the amount of nearby 
data used in fitting the line.  These smooth plots give an indication of the average trend of the 
hepatic responses by treatment group over the study time.  Figure 1 above depicts smooth plots 
of ALT in the left panel and AST in the right panel over days.  The NAC treatment group is in 
red (lighter).  It seems as though the NAC group initially exhibits increased levels of both ALT 
and AST.  However, as time passes the ALT and AST of both treatment groups equalize starting 
at 180 days from the surgery.  The graphs of Figure 2 below depict the lowess smooth plots of 
bilirubin on the left and INR on the right.  The bilirubin level for the NAC group is consistently 
above the placebo group throughout the entire study time.  It seems as though NAC increases 
bilirubin levels following OLT surgery.  The INR response is interesting.  The NAC group starts 
with longer blood clotting times, but by the end of the study the situation is reversed.  The 
placebo group seems to have longer clotting times compared to the treated group at the end of 
one year.   
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Figure 2: Lowess smooth over days bilirubin and INR 
Bilirubin is the left panel INR is the right panel NAC group in red (lighter) 
 
 
 
The distributions of all four raw hepatic responses are skewed over all time-points as shown by 
Figures 3-6.   In order to comply with the assumption of normally distributed responses the raw 
measures must assume a transformation.  The natural log transformation is used for the hepatic 
responses of ALT, AST, and bilirubin.  The reciprocal square root transformation is chosen for 
the response of INR.  Side by side histograms over time are displayed in Figures 3-6.  These 
figures show substantially more evidence for normally distributed measures after the respective 
transformations.  The transformed hepatic responses are systematically related to a linear 
function of the covariates.  Estimates of the effects of patient characteristics, including treatment 
status can be determined through an identity link with the response.   
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Figure 3: ALT histograms over days 
The distributions are shown over days the left panel contains the raw ALT and the right panel 
contains the log transformed ALT 
 
 
 
Figure 3 displays the transition in the distributions over time of ALT before and after the log 
transformation. The hepatic response of ALT does not seem normally distributed before 
transformation.  The left panel shows histograms over time of the raw ALT response, while the 
panel on the right consists of histograms of the natural log transformed response over the 
measured times. 
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Figure 4: AST histograms over days 
The distribution of AST is shown over days the left panel contains the raw AST while the right panel             
contains the log transformed AST 
 
 
 
Figure 4 is a comparison of the distributions over time of AST before and after the log 
transformation.  There is weak evidence for the normality assumption of AST before the natural 
log transformation.  The left panel consists of histograms of the raw AST response over time.  
The right panel is that of the natural log of AST over time. 
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Figure 5: Bilirubin histograms over days 
The distribution of bilirubin over days the left panel is that of the raw bilirubin the right panel is the 
log transformed bilirubin. 
 
 
 
Figure 5 compares the bilirubin measurements over time before and after a log transformation.  
The distribution of Bilirubin seems skewed to the right before the transformation is applied.  
After the transformation, there is strong visual evidence supporting the assumption that the 
response is normally distributed over time. 
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Figure 6: INR histograms over days 
INR distribution over days left panel is the raw INR level the right panel is the reciprocal square root 
transformation 
 
 
 
Figure 6 depicts the transition in distributions over time of INR before and after the reciprocal 
square root transformation. The hepatic response of INR is skewed toward lower values initially.  
Following the reciprocal square root transformation the INR values are more normally 
distributed. In summary, transformations for the responses are as follows:  
E Y ij
b c=X
k = 1
m
Bk X ik
whereY ij =
ln ALT
` a
ln AST
` a
ln Bilirubin
` a
INR@
1
2
ff
X^^^
^^\^
^^^^Z
 
Once the model fitting is completed, to revert back to the original scale an inverse transformation 
must be made.  When an estimate of the response is calculated for a patient, the inverse function 
is chosen to transform the E(Yij) back to the original scale of the response.  If Z is the original 
scale then 
Zij = exp Y ij
b c
if Y ij = ln ALT` a ; ln AST` a ; ln Bilirubin` a
Zij = Y ij@ 2 if Y ij = INR@
1
2
ff  
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In modeling the mean response for each of the four hepatic models, the continuous covariates are 
centered on the mean.  Centering the continuous covariates is done for two reasons.  First, the 
main goal of the analysis is to assess the effect of the treatment NAC on the response.  Second, 
centering the covariates makes sense for direct comparisons to an average patient.  In the 
population averaged model the baseline patient is a female who is not treated with average age, 
average amount of blood transfused, average donor serum sodium level, average donor age, and 
average BMI of the patient population.   
 
 
 
Table 2: Means of Patient Characteristics 
Patient  
Characteristic
  Mean 
Age   59.98 
Blood Trans.   7.52 
Don. Sodium   146.74
Don. Age   55.25 
BMI   29.13 
 
 
 
Table 2 shows the means of the patient characteristics.  The average OLT patient is 60 with a 
BMI of 29.13.  The average transfused blood received during surgery is 7.52.  The average donor 
serum sodium and age are 146.74 and 55.25 respectively.  
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2.2 NORMAL GEE MODELS FOR HEPATIC RESPONSES. 
 
Assuming the log transformed ALT is normally distributed and using an identity link for the 
GEE estimation procedure produces results listed in Table 3 . Estimates were computed using the 
xtgee command in STATA version 9.2.  The unadjusted estimates of Table 3 are a result of 
modeling a single covariate at a time to evaluate the effect of the covariate on the hepatic 
response.   The adjusted model shown in Table 4 contains only the covariates that were 
individually significant in the unadjusted model.  Estimates of the regression coefficients of the 
adjusted multi-variable model are obtained simultaneously.  For the GEE approach there are 
limited variable selection methods[1].  The only two variables retained from the univariate case 
are patient age, treatments status, and time. Although the effect of time on ALT is small it needs 
to be adjusted for in the final model. Treatment status was not significant according to the listed 
p-value, however it is the main focus of the analysis. NAC increase the ALT as shown by the 
positive coefficient.  However, there is weak evidence for this association as indicated by the 
respective p-value of 0.207. ALT is a measure of hepatic cell death, and an increase is unusual 
for the assumed protective effect of NAC. 
 
 
 
Table 3: Log ALT GEE model unadjusted estimates 
Unadjusted Estimates 
Variable Coeff. 95% C.I. P-Value 
NAC 0.157 (-0.1086 , 0.4225) 0.247 
Age -0.020 (-0.0336 , -0.0071) <0.01 
Male -0.088 (-0.4119 , 0.2354) 0.593 
Blood Trans. -0.013 (-0.0305 , 0.0035) 0.120 
Don. Sodium 0.008 (-0.0053 , 0.0222) 0.230 
Don. Age 0.002 (-0.0056 , 0.0097) 0.594 
BMI 0.009 (-0.0128 , 0.0310) 0.416 
Days -0.007 (-0.0080 , -0.0063) <0.01 
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Table 4: Log ALT GEE model adjusted estimates 
Adjusted Estimates 
variable  Coeff. 95% C.I. P-value 
NAC  0.156 (-0.0865 , 0.3988) 0.207 
Age  -0.015 (-0.0276 , -0.0017) 0.026 
Days  -0.007 (-0.0079 , -0.0062) <0.01 
Const.  5.285 (5.1258 , 5.4447) <0.01 
 
 
 
The model for ALT is as follows:  
Ln ALT
` a= 5.285 + treatmentgroupB0.156 @ age@ 60b cB0.018 @ daysB0.007 
Therefore the average 60 year old OLT patient who was treated with NAC has estimated ALT at 
one week following surgery of exp(5.285 + 0.156 – 0.049) = 219.64. On the other hand the 
estimated ALT for an average 60 year old patient on placebo is exp(5.285 – 0.049) = 187.91.  
The estimated difference of ALT between the treatment and placebo groups is not substantial. 
The age coefficient is negative.  Being older than average decreases the level of estimated ALT. 
 The information listed in Table 5 is the result of modeling the natural log of AST as a 
linear function of covariates using the GEE procedure.  The unadjusted estimates are the result of 
univariate models as was the case with the ALT response.  Patient age is the only covariate that 
may aide in determining the outcome of AST level.  Table 6 lists the results of the full AST 
model adjusted for the significant age variable, as well as treatment group and time. According 
to Table 6 there is no evidence that NAC has a significant effect on the outcome of AST as 
shown by the p-value of 0.740. 
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Table 5: Log AST model unadjusted estimates 
Unadjusted Estimates 
Variable  Coeff. 95% C.I. P-value 
NAC  0.0472 (-0.200 , 0.294) 0.708 
Age  -0.011 (-0.024 , -0.0015) 0.083 
Male  -0.125 (-0.491 , 0.169) 0.405 
Blood Trans.  -0.0041 (-0.0186 , 0.0104) 0.583 
Don. Sodium  0.0092 (-0.004 , 0.0231) 0.195 
Don. Age  0.0020 (-0.004 , 0.0086) 0.55 
BMI  0.0142 (-0.006 , 0.034) 0.176 
Days  -0.007 (-0.0084 , -0.0068) <0.01 
 
 
 
Table 6: Log AST model adjusted estimates 
Adjusted Estimates 
Variable  Coeff. 95% C.I. P-value
NAC  0.041 (-0.2008 , 0.2827) 0.740 
AGE  -0.006 (-0.0192 , 0.0076) 0.394 
Days  -0.007 (-0.0083 , -0.0067 <0.01 
Const.  5.245 (5.0888 , 5.4013) <0.01 
 
 
 
The effect of age on AST also shows a reduced association in the fully adjusted model 
compared to the univariate case.  The p-value changed from 0.083 in the univariate model to 
0.394 in the fully adjusted model. The change of significance is due to the adjustment for time. 
NAC is proposed to have an increasing effect on AST although the effect is close to zero. An 
increase in age causes the AST level to decrease.  Like the treatment effect, the amount of 
decrease in AST due to age is close to zero. The full form of the AST model is as follows:  
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Ln AST
` a= 5.24 + treatmentgroupB0.041@ age@ 60b cB0.006 @ daysB0.007 
The average aged patient on treatment at one week post-op has and estimated AST level equal to 
exp(5.24 + 0.041 - 0.049) = 187.16. The placebo patient at the same time has an almost identical 
estimated AST level of exp(5.24 – 0.049) = 179.65.  Since ALT and AST are closely related it is 
surprising that NAC would show a stronger association with ALT than with AST.  There may be 
some hidden confounding variable affecting the outcome.  Alternatively the mechanism of action 
of the treatment on these proteins may not be fully understood. 
The unadjusted estimates of covariate effects for bilirubin level are given in Table 7. The 
covariates of blood transfusion, donor serum sodium level, and donor age are significant as 
shown by the respective p-values of 0.06, 0.03, and 0.09.  The p-value of NAC is not significant 
at 0.388.  In the adjusted model of Table 8 there is no dramatic change in the strength of the 
association of the covariates.  
 
 
 
Table 7: Bilirubin model unadjusted estimates 
Unadjusted Estimates 
Variable Coeff. 95% P-value 
NAC 0.127 (-0.162 , 0.418) 0.388 
Age -0.002 (-0.017 , 0.012) 0.775 
Male -0.191 (-0.533 , 0.150) 0.272 
Blood Trans. 0.0195 (-0.0008 , 0.0398) 0.06 
Don. Sodium 0.0168 (0.0011 , 0.0326) 0.036 
Don. Age 0.007 (-0.0011 , 0.015) 0.092 
BMI 0.0182 (-0.007 , 0.0435) 0.158 
Days -0.006 (-0.0072 , -0.0054) <0.01 
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Table 8: Bilirubin model adjusted estimates 
Adjusted Estimates 
Variable Coeff. 95% C.I. P-value 
NAC 0.074 (-0.1759 , 0.3243) 0.561 
Blood Trans. 0.019 (0.0048 , 0.0330) <0.01 
Don. Sodium 0.015 (0.0028 , 0.0267) 0.016 
Don. Age 0.008 (-0.0012 , 0.0156) 0.022 
Days -0.006 (-0.0072 , -0.0054) <0.01 
Const. 1.23 (1.0312 , 1.4385) <0.01 
 
 
 
As one would expect donor age, donor serum sodium levels and amount of blood transfused have 
increasing effects on the level of Bilirubin.  In contrast to the hypothesized protective effect of 
the treatment on liver function, NAC increases the level of bilirubin, although not significantly.  
As in the model of AST, the evidence for significance of NAC in affecting the Bilirubin level is 
very weak with a p-value of 0.527.  The model for bilirubin is as follows: 
Ln Bilirubin
` a= 1.23 + treatmentgroupB0.074 + Blood transfused@ 7.52b cB0.019 +
Don A Sodium@ 146.74
` a
B0.015 + Don AAge@ 55.25b cB0.008 @ daysB0.006  
An estimate of bilirubin level for a patient from the treatment group with average blood 
transfused, average donor serum sodium, and average donor age at one week following the 
surgery is exp( 1.23 + 0.074 – 0.042) = 3.52.  For the same average patient from the placebo 
group the estimate is exp(1.23 – 0.042) = 3.28, which is nearly identical to the treated patient.  
NAC does not show an association with the level of bilirubin post-transplant.   
Tables 9 and 10 give the unadjusted and adjusted model estimates for the response of 
INR.  INR is a measure of blood coagulation time.  The transformation used to assume a 
normally distributed response is the reciprocal square root.  In this case a positive coefficient will 
decrease the INR, and a negative coefficient will cause the estimate of INR to increase.  This 
relationship is due to the inverse transformation used to obtain the raw INR level.  According to 
Table 9, the variables NAC patient age, and time are significant.  In the fully adjusted model of 
Table 10 the strength of the association of the treatment to the INR outcome is strengthened.  
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The p-value changes from 0.077 in the univariate case to 0.043 in the adjusted case.  The 
strength of the age association decreases slightly.   
 
 
 
Table 9: INR model unadjusted estimates 
Unadjusted Estimates 
Variable Coeff. 95% C.I. P-value 
NAC -0.022 (-0.0467 , 0.0024) 0.077 
AGE 0.002 (0.0004 , 0.0032) 0.010 
Male -0.020 (-0.0474 , 0.0060) 0.130 
Blood Trans. -0.001 (-0.0026 , 0.0007) 0.268 
Don. Sodium -0.001 (-0.0025 , 0.0003) 0.128 
Don. Age -0.0003 (-0.0009 , 0.0003) 0.330 
BMI -0.001 (0.8732 , 0.8981) 0.283 
Days 0.0001 (0.0 , 0.0003) 0.03 
 
 
 
Table 10: INR model adjusted estimates 
Adjusted Estimates 
Variable  Coeff. 95% C.I. P-value 
NAC  -0.023 (-0.0465 , -0.0007) 0.043 
Age  0.002 (0.0004 , 0.0032) 0.013 
Days  0.00015 (0.0 , 0.0003) 0.029 
Const.  0.893 (0.8757 , 0.9110) <0.01 
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The model of INR is as follows: 
INR@
1
2
fff= 0.893 @ treatmentgroupB@ 0.023 + age@ 60b cB0.002 + daysB0.00015 
so for a treated patient of average age 60 at one week following OLT surgery the estimated INR 
is (0.893 – 0.023 + 0.001 )(-2) = 1.318.  For a similar untreated patient the INR at one week is  
(0.893 + 0.001)(-2) = 1.251.  The treatment increases the time for blood coagulation.  Increased 
blood coagulation time is an indication of hepatic cell damage.  Increases in age result in 
decreases in INR and therefore decreases in clotting time.  This decrease in coagulation time 
with respect to age is suspect.  The contradictory evidence gives further support to a possible 
unknown confounding variable.   
It is interesting that the treatment NAC is shown to increase these indicators of hepatic 
cell damage.  There is weak evidence supporting the contention that the treatment is associated 
with levels of ALT, AST and bilirubin in the post-transplant period of one-year.  As supported 
by the respective p-values there is moderate evidence that the treatment is associated with 
increased levels of the prothrombin time.  The increase in  prothrombin time by NAC may be a 
result of increased cell damage. There could possibly be an unknown confounding variable that 
sits between the treatment effect and the mechanism for blood coagulation.  There may be an 
additional unknown hierarchical grouping variable associated with the hepatic function following 
OLT.  For example donor organ characteristics may play a larger role then assumed in 
determining hepatic functioning level.  Further analysis may need to include more information 
on donor characteristics.   
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3.0  APPLICATION OF ZIP GEE TO RENAL RESPONSE 
The distribution of ARF scores seems to be distributed as Zero Inflated Poisson at each time 
point because of the large proportion of zero scores at each time.  At the first time-point, which 
occurs prior to surgery, all patients have an ARF score of zero. Initially, each patient does not 
exhibit any risk of kidney failure. On the first day following OLT surgery only seven patients 
have scores designating some renal failure risk.  As days pass more patients switch from the 
structural portion of the model to the sampling portion. The structural zeros can be thought to be 
distributed as Bernoulli with probability (p) of the ARF score having the value zero.  Patients 
who are relatively healthy and resilient will have zero scores over all times and will not enter the 
sampling portion of the distribution.  Frail patients, on the other hand, transition from the zero 
state to the non-zero state.  They will fluctuate among all ARF levels during the study period. 
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3.1 ARF DATA 
ARF scores measure the condition of the patient’s renal functioning status.  As characterized by 
the RIFLE criteria.[7] The ARF score gives an indication of the damage done to the kidneys 
following liver transplantation.  Table 11 is a list of the proportion of zero ARF scores at each 
measured time-point.  The proportions of patients who have no risk of renal failure seem to 
decrease over time.  More patients transition from the zero-state and become part of the non-zero 
state as time passes.   
 
 
 
Table 11: Proportion of zero ARF at each time 
p estimate
P1 .999 
P2 .905 
P3 .819 
P4 .704 
P5 .685 
P6 .671 
P7 .766 
P8 .625 
P9 .555 
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Figure 7: Distribution of ARF by treatment group over days  
Placebo group is in the left panel while treatment group is in the right panel 
 
 
 
The distribution of ARF scores over time in days is shown in Figure 7.  The left panel consists of 
the placebo group.  The panel on the right shows the treatment group.  There is a large proportion 
of zero ARF scores at each time-point.  While the non-zero values that denote some risk of renal 
failure are sparse and fluctuate over all times.  Also note the small proportion of ones in the 
treatment group at the ending three time-points compared to the proportion of ones in the 
placebo group at the same times.  
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Figure 8: Spaghetti plots ARF over days 
The panel on the left depicts the placebo group the panel on the right depicts the treatment group 
 
 
 
A closer look at the conditions of each individual patient over time is given in the graphs of 
Figure 8 and 9. Figure 8 depicts spaghetti plots of each individual patient. The graphs are 
connected line plots of the ARF scores for each patient over the one-year study time.  The scores 
of the treatment group have a maximum of 3.  On the other hand, the scores for the placebo 
group not only surpass 3 but seem to increase over the study time compared to the treatment 
group. Figure 9 depicts the fitted values of ARF score over time.  Again, the trend seems to be 
increasing in the placebo group and decreasing in the control group.  NAC seems to be 
decreasing the ARF score at each time-point.    There is substantial graphical evidence that NAC 
has a protective effect on the kidneys following OLT surgery. 
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Figure 9: Fitted Values ARF over days 
The panel on the left is the placebo group the panel on the right is the treatment group 
 
 
 
Figure 10: Smoothed ARF score over days by treatment group 
The left panel uses bandwidth of 0.6 right panel uses bandwidth of 0.8 
 
 
 
A locally weighted smooth-plot (lowess) was applied to the ARF scores. The lowess 
method uses a first degree polynomial least squares linear fitting method to smooth the discrete 
response data over time. The treatment group shows a marked difference in ARF scores.  The 
difference between the treatment and control groups is supported by this smooth plot.  The 
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treatment group exhibits lower ARF scores compared to the placebo group.  Notice that ARF is 
highly skewed toward zero at the first time as one would expect from a ZIP distribution.  The left 
graph of Figure 10 uses a bandwidth of 0.6 while the graph on the right uses a bandwidth of 0.8.  
The bandwidth dictates the amount of nearby data used in fitting the line. 
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3.2 ZIP MODEL FOR ARF SCORE 
 
Initial parameter estimates are obtained by fitting the GEE model using the natural log link of the 
Poisson distribution for ARF.  Molenbergh[15] advises to start with univariate estimates in the 
Fisher algorithm.  The Poisson model does not take into account the high proportion of zero 
scores at each time-point. Initial estimates of the pj at each time-point are taken to be the 
proportion of zero ARF at each time as listed in Table 11.  Table 12 gives the initial estimates 
obtained through Poisson GEE. 
 
 
 
Table 12: Initial unadjusted model estimates for ARF GEE 
 Variable Coeff. P-value
NAC -0.146 0.612 
Age -0.026 0.155 
Male 0.070 0.830 
Blood Trans. -0.040 0.211 
Don. Sodium 0.027 0.082 
Don. Age -0.006 0.336 
BMI 0.010 0.673 
 
 
 
 
 
 
 
 
 
 
As mentioned in Section 1.3  The ARF response is assumed to be distributed as: 
Y ij =
0 , ~Bernoulli p j
b c
y, ~ Poisson λ` a with probability 1@ p jb c , y ≥ 1
X^^\^
Z^  
For a ZIP distributed random variable as given by [9]: 
E Y
@ A = 1@ pb c λ
Var Y
@ A = λ 1@ pb cB 1 + λ pB C 
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Modeling the ZIP distributed longitudinal response as a function of covariates is accomplished 
through the GEE method previously described.  The mean is modeled through component 
parameters as follows: 
E Y ij
B C = 1@ p jb c λ  
Where p is modeled as a logit regression on time-dependent intercepts: 
p j^ = e
γ j
1 + eγ j
ffffffffff 
In order to test the association of covariates with emphasis on the treatment, the parameter  
lambda is modeled as an exponential form of the covariate vector X. To introduce the covariate 
patient characteristics: The parameter lambda is modeled as a time-independent function of 
covariates given by: 
λ^ = eXk = 0
m
X ik βk  
The expectation and variance of the model is then given by:   
E Y ij
B C = 1@ p jb c eXk = 1
m
X ik βk
Var Y ij
B C = eXk = 1m X ik βk 1@ p jb cB 1 + eXk = 1
m
X ik βk p j
F G 
The covariates are only involved in the poisson state.  Since the ZIP model has a defined 
marginal mean the GEE approach can be applied.  The Fisher algorithm is used to solve the score 
as in the general case.  MATLAB was used to evaluate the modified Fisher algorithm proposed 
by Liang and Zeger [10].  For the MATLAB code refer to Appendix A.  The exchangeable 
correlation structure is assumed.  As mentioned previously the exchangeable correlation signifies 
the assumption of constant correlation among all time-points.  One would initially assume the 
correlation among time intervals is constant because each time interval is of a different size. The 
main goal is to understand the effect of NAC on renal functioning as measured by ARF score at 
each time.  The correlation over time is a nuisance as is ignored to obtain efficient parameter 
estimates of the treatment effect.  The exchangeable alpha is estimated by the following:   
                                          
α^ = 1N
ffffX
i = 1
N 1
ni ni@ 1
b cffffffffffffffffX
j ≠ k
eij eik
eij =
yij@µ ij
Var uij
b crwwwwwwwwwwww
ffffffffffffffffff  
 32 
3.3 RENAL ANALYSIS RESULTS  
The ZIP GEE model explained above produces the following parameter estimates shown in   
Table 13.  The p-value of the treatment effect of 0.1047 indicates a moderate association with the 
outcome measure of ARF score as an indicator of  renal function status.  Furthermore the effect 
of NAC as given by the coefficient of -0.303 is to reduce the ARF score.  Univariate models of 
the other patient characteristics do not produce significant changes in ARF score.  Also, the 
estimates of the effects are substantially smaller compared to NAC. 
 
 
 
Table 13: ZIP GEE model for ARF score univariate estimates 
Unadjusted Estimates 
Variable  Coeff. 95% C.I. P-Value 
NAC  -0.303 (-0.7761 , 0.1701) 0.1047 
Age  -0.0017 (-0.0272 , 0.02378) 0.446 
Male  0.0117 (-0.4844 , 0.5079 0.518 
Blood Trans.  -0.020 (-0.0692 , 0.0284) 0.207 
Don. Sodium  0.011 (-0.0147 , 0.0372) 0.801 
Don. Age  -0.003 (-0.0150 , 0.0087) 0.302 
BMI  0.01 (-0.0266 , 0.0466) 0.701 
 
 
 
Estimates of the time-dependent parameters pj using NAC as the single covariate are given in 
Table 14. The proportion of zero ARF prior to surgery is omitted because it is one. 
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Table 14: Estimates of pj of ZIP GEE with NAC covariate 
Pj Estimate
P1 0.8064 
P2 0.6400 
P3 0.4699 
P4 0.4312 
P5 0.3704 
P6 0.5941 
P7 0.3215 
P8 0.2056 
 
 
 
The estimates of the proportion of zero ARF scores computed from the ZIP GEE seem to 
decrease over time.  One can construct a Wald statistic to test the hypothesis that the pj’s are all 
equal.  This test will indicate whether the proportion of zero ARF scores change over time.  The 
Wald test is defined as follows: 
V p = cov p j^
B C
V pC = CBV pBC .
where:
C =
1 @ 1 0 0 0 0 0 0 0
1 0 @ 1 0 0 0 0 0 0
1 0 0 @ 1 0 0 0 0 0
1 0 0 0 @ 1 0 0 0 0
1 0 0 0 0 @ 1 0 0 0
1 0 0 0 0 0 @ 1 0 0
1 0 0 0 0 0 0 @ 1 0
1 0 0 0 0 0 0 0 @ 1
HLLLLLLLLLLLLLLJ
IMMMMMMMMMMMMMMK
then:
χ2 p@ 1b c = p^ . B V pCb c@ 1B p^
 
The chi-square statistics is 166.46 giving a p-value of much less than 0.01.  The proportions of 
zero ARF responses are not constant over time.  There are patients who transition from the zero 
state and enter the non-zero state of the ZIP distributed response.  The model for ARF is as 
follows: 
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ARF^ = 1@ ptime
b c
etreatmentgroupB @ 0.303
` a
 
As an example, the expected ARF for a patient on NAC treatment at the 14th day is (1-
0.4699)*exp(-0.303) = 0.3914 while the expected ARF for a patient in the placebo group at the  
14th day is  (1-0.4699) = 0.530.  Notice that a constant is not included in the model.  A constant 
in the above model will introduce a scale of the term (1-pj).  This scale would cause the estimate 
of the constant to be non-identifiable from the parameter (pj) which is the proportion of zero 
ARF scores. It would not be possible to separate the estimate of pj from the estimate of the 
constant. The graphical analysis, as shown by the locally weighted scatter-plot smooth of Figure 
10, reinforces the hypothesis that NAC is protective against renal damage during OLT surgery.  
This analysis warrants further investigation of the NAC as a prophylaxis for renal damage 
following OLT surgery.   
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4.0  DISCUSSION 
The GEE approach was applied to the hepatic responses of OLT patients in order to elucidate the 
effect of the treatment NAC on liver dysfunction.  NAC is thought to be protective against 
damage by oxidative stress following transplant surgery.  The hepatic responses of ALT , AST , 
Bilirubin, and INR had to be transformed in order to achieve the assumption of a normally 
distributed response.  The GEE estimates of treatment effect contradicts the hypothesis that NAC 
is protective against liver damage following OLT.  All four indicators of hepatocyte cell damage 
increases in association with the treatment.  There is a strong possibility that an unknown 
confounding variable exists which is affecting the status of liver function following surgery.  
One possibility is the effect of the donor liver status in the outcome of liver graft performance.  
The status of the donor liver would have a large influence on the functioning status of the 
transplant patient. Further analysis of the hepatic response should include more information 
concerning donor liver characteristics.  
The ARF scores, as a measure of renal dysfunction following surgery, were shown to 
exhibit the unique Zero-Inflated Poisson distribution.  Graphical analysis supported a treatment 
effect of NAC in protecting against renal dysfunction. Initial estimates using a log link of an 
assumed poisson distributed response yielded inaccurate effects of the treatment. The GEE 
procedure as proposed by Liang and Zeger [10] was used to estimate the true treatment effect of 
NAC.  The GEE procedure easily accommodated the uniquely distributed ARF response.  
Further investigation into the effectiveness of NAC as a prophylaxis to prevent renal damage is 
necessary. 
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APPENDIX A 
MATLAB PROGRAM FOR ZIP GEE        
% %  the initial data must consist of  
% %  Response Scores (ARF) 
% %  Initial exchangeable correlation alpha 
% %  covariate vector (nac age male donage donna bmi) 
% %  Some Intial parameters the p-vector and the beta-vector 
  
  
%%  Initial Estimates 
  
alpha = .303; 
  
p = [.9999;.9054;.8194;.7042;.6857;.6714;.7666;.6250;.5555]; 
  
gamma = log(p./(1-p)); 
  
%univariate beta estimations from 
%  xtgee poisson  [-.146;-.026;.07;-.04;.027;-.006;.01] 
  
beta = -.146; 
  
parm = [gamma; beta(:)]; 
  
parmnew = parm; 
  
R = alpha*ones(9); 
  
for w=1:9; 
    for z=1:9; 
        if w == z; 
            R(w,z)=1; 
        end; 
    end; 
end; 
  
% Multivariate design matrix 
% desX = [nac (age-mean(age)) male (rbc-mean(rbc)) (donna-mean(donna))  
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%   (donage-mean(donage)) (bmi-mean(bmi))]; 
  
desX = [nac]; 
  
q = 1 ; 
  
tol = 1; 
  
  
%% global loop starts here 
while (q < 500) && (tol > .0001 ) 
                
                 beta = parmnew(10); 
                  
                 gamma = parmnew(1:9); 
     %% the following keeps p bounded in [0,1]            
                 p = exp(gamma)./(1 + exp(gamma)); 
     
%%  The initilization of estimation sum terms. 
  
%  Initialize the iterative coefficient estimate sums 
  
sumterm1 = 0*ones(10); 
sumterm2 = 0*ones(10,1); 
  
%  Initialize Standard Error Sums 
Mnull = zeros(10); 
Mone = zeros(10); 
RobustMone = zeros(10); 
  
    
%% inner loop starts here Sum over panels (patients) 
  
for i = 1:74 
  
% vary is a column vector of marginal variances for patient i.    
  
vary = exp(sum(desX(i,:)'.*beta))*(1-p).*(1 + exp(sum(desX(i,:)'.*beta))*p) ; 
  
% Marginal Co-Variance Matrix 
  
V = sqrt(diag(vary))*R*sqrt(diag(vary)) ; 
  
  
%% Creating the Expectation column vector. 
  
EY = (exp(sum(desX(i,:)'.*beta))*(1-p)) ; 
  
  
%% The following creates the Dmu matrix 
  
f = -(exp(sum(desX(i,:)'.*beta)))*eye(9) ; 
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l = (desX(i,:)'.*exp(sum(desX(i,:)'.*beta)))'; 
  
m = (1-p)*l; 
  
Dmu = [f m] ;  
  
%% Now for the Sums over panels for parameter estimate 
  
% the terms are for i and must be  
% summed over all patients. 
  
term1 = Dmu'*inv(V)*Dmu ; 
  
term2 = Dmu'*inv(V)*(arf(i,:)'-EY) ; 
  
sumterm1 = sumterm1 + term1; 
sumterm2 = sumterm2 + term2; 
  
%%   for the std. errors  
  
mnull = Dmu'*inv(V)*Dmu; 
  
mone = Dmu' * inv(V) * ((arf(i,:)' - EY) * (arf(i,:)' - EY)') * inv(V) * Dmu; 
  
moneR = Dmu' * inv(V) * (cov(arf)) * inv(V) * Dmu; 
  
Mnull = Mnull + mnull; 
  
Mone = Mone + mone; 
  
RobustMone = RobustMone + moneR; 
  
end 
%% End of Inner loop over panels 
  
  
%% Updating the parameter estimates. 
  
 %  Used to check the previous parameter  
oldparm = parmnew; 
  
parmnew = parmnew + (inv(sumterm1)*sumterm2); 
  
 %  A tolerance vector 
tolvec = abs(parmnew - oldparm); 
  
 %  setting the tolerance equal to the max of any individual difference 
tol = max(abs(parmnew - oldparm)); 
  
 %   Go to next iteration 
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q = q+1; 
  
end 
  
%% End of Outer loop for each updating iteration. 
  
  
%% Outputting the Results of the Estimating Equations 
  
format long g 
  
parmnew 
  
% Naive Beta Variance 
NVparm = diag(inv(Mnull)*Mone*inv(Mnull)); 
  
% Robust Beta Variance 
RVparm = diag(inv(Mnull)*RobustMone*inv(Mnull)) 
  
% Wald using Naive estimate variance 
NWald = parmnew ./ (sqrt(NVparm)); 
  
% Wald using Robust estimate variance 
Wald = parmnew ./ (sqrt(RVparm)) 
  
q 
  
tol 
  
gamma = parmnew(1:9); 
  
%  estimates of proportion of zeros at each time-point 
p = exp(gamma)./(1 + exp(gamma)); 
  
nacstderr = sqrt(RVparm(10)) 
  
nacest = parmnew(10) 
  
nacZ = Wald(10) 
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